Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

BUY
$7.14 - $8.53 $25,054 - $29,931
3,509 Added 4.42%
82,898 $596,000
Q4 2022

Feb 13, 2023

BUY
$8.22 - $10.76 $161,276 - $211,111
19,620 Added 32.83%
79,389 $652,000
Q3 2022

Nov 10, 2022

BUY
$8.95 - $12.0 $164,680 - $220,800
18,400 Added 44.48%
59,769 $630,000
Q2 2022

Aug 12, 2022

BUY
$6.46 - $10.02 $267,243 - $414,517
41,369 New
41,369 $382,000
Q4 2020

Feb 12, 2021

SELL
$2.27 - $3.3 $43,350 - $63,020
-19,097 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$2.14 - $12.02 $17 - $96
8 Added 0.04%
19,097 $43,000
Q2 2020

Aug 12, 2020

BUY
$8.88 - $11.15 $169,510 - $212,842
19,089 New
19,089 $196,000

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0

About BELLUS Health Inc.


  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.